Beijing, China
neoX Biotech, founded in 2018, is a cutting-edge biotech company headquartered in Beijing, China, with additional research teams in Shanghai, China, and Boston, USA. Specializing in Computation-Driven Drug Design, it leverages artificial intelligence (AI), state-of-the-art biophysics, and high-throughput experimentation to develop innovative therapeutics aimed at meeting unmet medical needs.
The company targets the discovery of macromolecular and multi-specific drug modalities by gaining deep insights into dynamic protein-protein interactions (PPIs). Their key offerings include neoBiologics (highly selective antibody/nanobody and protein drugs) and neoDegrader (Targeted Protein Degradation drugs, such as PROTACs and Molecular Glues).
With several antibody-based drugs and PROTAC degraders approaching candidate-selection or IND-enabling stages, neoX Biotech is actively seeking licensing opportunities and experienced strategic partners to further its growth and establish enduring collaborations.
